Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease

Guangzhou University of Traditional Chinese Medicine650 enrolled

Overview

This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass spectrometry (LC-MS/MS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease

The problem of population aging is getting worse, the prevalence of senile dementia is increasing, and Alzheimer's disease (AD) is the most common type of dementia. There is no effective treatment for AD. Most interventions can only alleviate the condition and delay the development. Therefore, early diagnosis and prevention of AD are extremely important. However, the current diagnostic measures are not suitable for clinical promotion due to their traumatic nature, so there is an urgent need for a more suitable clinical early identification and diagnosis method. Proteomics research technology is the leading research technology in China. It can be applied to research on disease markers, pathogenesis, and drug target discovery. Therefore, this study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass spectrometry (LC-MS/MS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease

Study Type

OBSERVATIONAL

Enrollment

650

Conditions

Alzheimer Disease, Early Onset Protein; Disease

Eligibility

Sex: ALLMin age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Older than 55-year-old，male or female. 2. patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD 3. Complete self-rating scale for memory impairment (AD-8 scale) 4. Those who agree to participate in clinical research and sign informed consent. Exclusion Criteria: 1. Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia; 2. Pregnant or lactating women;

Locations (1)

Guangdong Province Hospital of Tradtional Chinese Medicine

Guangzhou, Guangdong, China

RECRUITING

Outcomes

Primary Outcomes

Changes in the protein expression profile of urine and saliva

Proteomic expression of urine and saliva in each group will be tested use Protein liquid chromatography/mass spectrometry detection.

Time frame: An Average of 1 year

Secondary Outcomes

Change of the cognitive function every year

Mini-mental State Examination (MMSE) score for the the cognitive function assessment. The total score in MMSE ranges from 0 to 30, and higher scores indicate better cognition.

Time frame: An Average of 1 year

Changes in plasma protein expression profile every year

Proteomic expression of plasma in each group will be tested use Protein liquid chromatography/mass spectrometry detection.

Time frame: An Average of 1 year

Variation characteristics of gut microbiome every year

Bacterial genomic DNA was extracted from faecal and tongue coating samples of each group using 16S RNA sequencing and analysis

Time frame: An Average of 1 year

Central Contacts

jianwen guo, Dr

CONTACT

13724899379 306247680@qq.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.